-
10:53:03 AM

MCRB Stock News

05/30/23 4:00 PM
Nasdaq : MCRB
fda approval
Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™
Seres Therapeutics, Inc., a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults...
RHEA-AI
neutral
05/09/23 7:00 AM
Nasdaq : MCRB
earnings
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
Seres Therapeutics, Inc., a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates. The approval of VOWST marks Seres’ transformation to a commercial organization and provides definitive validation of the promise of our microbiome technology platform,” said Eric Shaff, President and...
RHEA-AI
neutral
05/09/23 7:00 AM
Nasdaq : MCRB
clinical trial
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome
Seres Therapeutics, Inc., a leading microbiome therapeutics company, today reported initial clinical data about SER-155. SER-155 is an oral, cultivated bacterial consortia investigational therapeutic designed to prevent enteric-derived infections and resulting blood stream infections, as well as induce immune tolerance responses to reduce the...
RHEA-AI
neutral
05/05/23 7:00 AM
Nasdaq : MCRB
conferencesearnings
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023
Seres Therapeutics, Inc., a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 9, 2023 at 8:30 a.m. ET to discuss first quarter results and provide a general business update, including initial SER-155 Phase 1 b safety and pharmacology results from study Cohort 1..
RHEA-AI
neutral